Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
UNUnicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc. (UNCY)

NASDAQ Capital Market · Currency in USD
$3.89 ▼ -0.05 (-1.27%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.89 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.94
Open
$3.95
Day's Range
$3.71 – $3.95
52 Week Range
$3.35 – $8.74
Volume
1,212,401
Avg. Volume
1,350,244
Market Cap
$106.56M
Beta (5Y Monthly)
1.82
PE Ratio (TTM)
--
EPS (TTM)
-$1.31
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$22.00

Profile: Unicycive Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
21
CEO
Shalabh K. Gupta

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.33 · Revenue est. $902.78K
DateEst.Actual
Aug 12, 2026-$0.47-$0.06Beat
May 12, 2026-$0.55-$0.54Beat
Mar 30, 2026-$0.46-$0.82Miss
Nov 12, 2025-$0.59-$0.33Beat
Aug 14, 2025-$0.70-$0.52Beat
May 14, 2025-$0.67-$0.50Beat

Analyst view

Consensus price target
$22.00 ▲ +465.6%
Range $22.00 – $22.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on UNCY and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.